Entrapment of Peptidoglycans and Adamantyltripeptides into Liposomes: An HPLC Assay for Determination of Encapsulation Efficiency

Journal of Liposome Research

Volumn 13, Issue 3-4, 2003, Pages 279-294

  Frkanec, Ruža ^a   Travaš, Dijana ^a   Krstanović, Marina ^a   Špoljar, Beata Halassy ^a   Ljevaković, Durdica ^a   Vranešić, Branka ^a   Frkanec, Leo ^b   Tomašić, Jelka ^a  

^a INSTITUTE OF IMMUNOLOGY   (Croatia)

^b RUDER BO KOVI INSTITUTE   (Croatia)

Author keywords

Adamantyltripeptides; Encapsulation; HPLC; Liposomes; Peptidoglycan monomer

Indexed keywords

(ADAMANT 1 YL)ACETYL PEPTIDOGLYCAN; ADAMANTANE DERIVATIVE; IMMUNOMODULATING AGENT; LIPOSOME; MONOMER; N (TERT BUTYLOXYCARBONYL)TYROSYL PEPTIDOGLYCAN; PEPTIDOGLYCAN; TRIPEPTIDE; UNCLASSIFIED DRUG;

ARTICLE; DIASTEREOISOMER; DRUG FORMULATION; DRUG STABILITY; ENCAPSULATION; FILM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; TEMPERATURE DEPENDENCE;

EID: 0344851799     PISSN: 08982104     EISSN: None     Source Type: Journal    
DOI: 10.1081/LPR-120026452     Document Type: Article

References (55)

1. Sharma A, Sharma US. Liposomes in drug delivery: progress and limitations. Int J Pharm 1997; 154:123-140.
2. Lasić DD. Novel applications of liposomes. Trends Biotechnol 1998; 16:307-327.
3. Gursoy A. Liposome-encapsulated antibiotics: physicochemical and antibacterial properties, a review. S.T.P. Pharma Sciences 2000; 10(4):285-291.
4. Pinto H, Andremont A, Couvreur P. Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications. Int J Antimicrobial Agents 2000; 13:155-168.
5. Massing U, Fuxius S. Liposomal formulations of anticancer drugs: selectivity and effectiveness. Drug Resistance Update 2000; 3:171-177.
6. Naessander UK, Storm G, Peeters P, Crommelin D. Liposomes. Biodegradable Polymers as Drug Delivery Systems. In: Chasin M., Langer R., eds. New York: Marcel Dekker, Inc., 1990:261-338.
7. Alving CR. Liposomes as carriers of antigens and adjuvants. J Immunol Methods 1991; 140:1-13.
8. Alpar HO, Ward KR, Williamson ED. New strategies in vaccine delivery. S.T.P. Pharma Sciences 2000; 10(4):269-278.
9. Lian T, Ho RJY. Trends and development in liposome drug delivery systems. J Pharm Sci 2001; 90:667-680.
10. Ambrosch F, Weidermann G, Jonas S, Althaus B, Finkel B, Gluck R, Herzog C. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine 1997; 15:1209-1213.
11. Gregoriadis G, McCormack B, Obrenovic M, Saffie R, Zadi B, Perrie Y. Vaccine entrapment in liposomes. Methods 1999; 19:156-162.
12. Perrie Y, Gregoriadis G. Liposome-entrapped plasmid DNA: characterisation studies. Biochim Biophys Acta 2000; 1475:125-132.
13. Antimisiaris SG, Jayasekera P, Gregoriadis G. Liposomes as vaccine carriers. Incorporation of soluble and particulate antigens in giant vesicles. J Immunol Methods 1993; 166:271-280.
14. Killion JJ, Fidler IJ. Therapy of cancer metastasis by tumoricidal activation of tissue macrophages using liposome encapsulated immunomodulators. Pharmacol Ther 1998; 78:141-154.
15. Turanek J, Zaluska D, Vacek A, Borkovceva P, Thurnvaldova J, Blaha L, Mašek K. Stimulation of nonspecific immunity, haemopoiesis, and protection of mice against radiation injury by 1-adamantylamide-L-alanyl-D-isoglutamine incorporated in liposomes. Int Immunopharmacol 2001; 1:167-175.
16. Krup OC, Kroll I, Boese G, Falkenberg FW. Cytokine depot formulations as adjuvants for tumor vaccines. I. Liposome-encapsulated IL-2 as a depot formulation. J Immunother 1999; 22(6):525-538.
17. O'Hagan DT. ed. Vaccine adjuvants: Preparation Methods and Research Protocols. Totowa, New Jersey: Humana Press, 2000:342 pp.
18. Giedlin MA. Cytokines As Vaccine Adjuvants: The Use of Interleukin-2. Vaccine adjuvants: Preparation Methods and Research Protocols. In: O'Hagan DT. ed. Totowa, New Jersey: Humana Press, 2000:283-299.
19. Allison AC. The role of cytokines in the action of immunological adjuvants. Vaccine Design: The Role of Cytokine Networks. In: Gregoriadis G., McCormack B., Allison AC., eds. New York: Plenum Press, 1997:1-9.
20. Seidl PH, Schleifer KH, Eds. Biological Properties of Peptidoglycans. Berlin: W. de Gruyter, 1986:436 pp.
21. Stewart-Tull DES. Immunostimulation with Peptidoglycan or its Synthetic Derivatives. Prog Drug Res 1988; 32:305-328.
22. Tomašić J, Hanzl-Dujmović I, Špoljar B, Vranešić B, Šantak M, Jovičić A. Comparative study of the effects of peptidoglycan monomer and structurally related adamantyltripeptides on humoral immune response to ovalbumin in the mouse. Vaccine 2000; 18:1236-1243.
23. Ellouz F, Adam A, Ciorbaru R, Lederer E. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem Biophys Res Commun 1974; 59:317-325.
24. Azuma I. Synthetic immunoadjuvants: application to nonspecific host stimulation and potentation of vaccine immunogenicity Vaccine 1992; 10:1000-1006.
25. Urleb U, Krbavčič A, Sollner M, Kikelj D, Pečar S. Synthesis of phthalimidodesmuramylpeptide analogues as potential immunomodulating agents. Arch Pharm (Weinheim) 1995; 328:113-117.
26. Kikelj D, Pečar S, Kotnik V, Štalc A, Wraber-Herzog B, Simičič S, Ihan A, Klamfer L, Povšič L, Grahek R, Suhadolc E, Hočevar M, Honig H, Rogi-Kohlenprath R. N-(trans-2-(2′ -(acetylamino)cyclohexyl(oxy(acetyl(-L-alanyl-D-glutamic acid: a novel immunologically active carbocyclic muramyl dipeptide analogue. J Med Chem 1998; 41:530-539.
27. Keglević D, Ladešić B, Tomašić J, Valinger Z, Naumski R. Isolation procedure and properties of monomer unit from lysozyme digest of peptidoglycan complex excreted into the medium by penicillin-treated Brevibacterium divaricatum mutant. Biochim Biophys Acta 1979; 585:273-281.
28. Tomašić J, Sesartić, Lj.; Martin SA, Valinger Z, Ladešić B. Comparative susceptibility of a peptidoglycan monomer from Brevibacterium divaricatum and its anhydromuramyl analogue to hydrolysis with N-acetylmuramyl-L-alanine-amidase. J Chromatogr 1988; 440:405-414.
29. Matter H, Szilagyi L, Forgo P, Marinić, Ž.; Klaić B. Structure and dynamics of a peptidoglycan monomer in aqueous solution using NMR spectroscopy and simulated annealing calculations. J Am Chem Soc 1997; 119:2212-2223.
30. Vranešić B, Ljevaković D, Tomašić J, Ladešić B. A competitive radioimmunoassay for peptidoglycan monomer. Clin Chim Acta 1991; 202:23-38.
31. Hršak I, Ljevaković D, Tomašić J, Vranešić B. Preparation, properties and biological activity of tert-butyloxycarbonyl-L-tyrosyl peptidoglycan monomer. Immunotherapy of Infections. In: Masihi N, ed. New York: Marcel Dekker, 1994;249-257.
32. Ljevaković D, Tomašić J, Šporec V, Halassy Špoljar B, Hanzl-Dujmović I. Synthesis of novel adamantylacetyl derivative of peptidoglycan monomer-biological evaluation of immunomodulatory peptidoglycan monomer and respective derivatives with lipophilic substituents on amino group. Bioorg Med Chem 2000; 8:2441-2447.
33. Vranešić B, Tomašić J, Smerdel S, Kantoci D, Benedetti F. Synthesis and antiviral activity of novel adamantyltripeptides. Helv Chim Acta 1993; 76:1752-1758.
34. Sava G, Pacor S, Vranešić B, Tomašić J, Cocchietto M. Modification of the growth of MCa mammary carcinoma of CBA mouse by new adamantyl-peptides. Int J Oncol 1993; 2:607-612.
35. Dašić G, Pacor S, Bergamo A, Salerno G, Vranešić B, Jukić R, Tomašić J, Sava G. Effects of L-(adamant-2-yl)glycyl-L-alanyl-D-isoglutamine on the antitumor action of cyclophosphamide, 5-FU, cisplatin and dacarbazine on advanced carcinomas of the mouse. Int J Oncol 1994; 5:275-281.
36. Vranešić B, Tomašić J, Ljevaković D, Hršak I. Biological activity of novel adamantyltripeptides with the emphasis on their immunorestorative effect. Immunotherapy of Infections. In: Masihi N, ed. New York: Marcel Dekker, Inc., 1994:241-248.
37. Mažuran, R, Vranešić B, Ikić-Sutlić M, Šimrak D, Tomašić J. Isomers of D,L-(adamant-2-yl)-glycyl-L-alanyl-D-isoglutamine induce intereferon production in human mononuclear cells. Period Biol 1996; 98(3):305-310.
38. Halassy Špoljar B, Čimbora T, Hanzl-Dujmović I, Dojnović B, Sabioncello A, Krstanović M, Tomašić J. Influence of adjuvant-active peptidoglycan monomer on specific T cell responses in mice. Vaccine 2002; 20:3543-3550.
39. 14C-labeled peptidoglycan monomer in mice. I. Identification of the monomer and the corresponding pentapeptide in urine. Biochim Biophys Acta 1980; 629:77-82.
40. Valinger Z..; Ladešić B, Tomašić J. Partial purification and characterisation of N-acetylmuramyl-L-alanine amidase from human and mouse serum. Biochim Biophys Acta 1982; 701:63-71.
41. Valinger Z, Ladešić B, Hršak I, Tomaš ić J. Relationship of metabolism and immunostimulating activity of peptidoglycan monomer in mice after three different routes of administration. Int J Immunopharmac 1987; 9:325-332.
42. Halassy B, Krstanović M, Frkanec R, Tomašić J. Adjuvant activity of peptidoglycan monomer and its metabolic products. Vaccine 2003; 21:971-976.
43. Daemen T, Dontje BHJ, Regts J, Scherphof GL. Chemo-immunotherapy of murine liver metastases with 5-fluorouracil in combination with liposomeencapsulated muramyl dipeptide. J Immunother 1993; 13:(1), 31-35.
44. Asano T, Matsushima K, Kleinerman ES. Liposome-encapsulated muramyl tripeptide up-regulates monocyte chemotactic and activating factor gene expression in human monocytes at the transcriptional and post-transcriptional levels. Cancer Immunol Immunother 1994; 38:16-22.
45. Gianan MA, Kleinerman ES. Liposomal muramyl tripeptide (CGP 19835A lipid) therapy for resectable melanoma in patients who were at high risk for relapse: an update. Cancer Biother Radiopharm 1998; 13(5):363-368.
46. Moribe K, Maruyama K, Iwatsuru M. Spectroscopic investigation of the molecular state of nystatin encapsulated in liposomes. Int J Pharm 2000; 201:37-49.
47. Canto GS, Dalmora SL, Oliveira AG. Piroxam encapsulated in liposomes: characterization and in vivo evaluation of topical anti-inflammatory effect. Drug Dev Ind Pharm 1999; 25(12):1235-1239.
48. Youan BB, Benoit MA, Rollmann B, Riveau G, Gillard J. Protein-loaded poly(ε-caprolactone)microparticles. II. Muramyl dipeptide for oral controlled release of adjuvant. J Microencapsul 1999; 16(5):601-612.
49. Kirilenko VN, Gregoriadis G. Fat soluble vitamins in liposomes: studies on incorporation efficiency and bile salt induced vesicle disintegration. J Drug Target 1993; 1:361-368.
50. Ramaldes GA, Deverre JR, Grognet JM, Puisieux F, Fattal E. Use of an enzyme immunoassay for the evaluation of entrapment efficiency and in vitro stability in intestinal fluids of liposomal BSA. Int J Pharm 1996; 143: 1-11.
51. Lasić DD. Liposomes: From Physics to Applications. Amsterdam: Elsevier, 1993:559 pp.
52. 14C(peptidoglycan monomer into liposomes. Effect on metabolism and immune response in mice. Biochim Biophys Acta 1982; 716:217-223.
53. Krstanović M, Frkanec R, Vranešić B, Ljevaković D, Šporec V, Tomašić J. Reversed-phase high-performance liquid chromatographic method for the determination of peptidoglycan monomers and structurally related peptides and adamantyltripeptides. J Chromatogr B 2002; 773:167-174.
54. Dipali SR, Kulkarni SB, Betageri GV. Comparative study of separation of nonencapsulated drug from unilamellar liposomes by various methods. J Pharm Pharmacol 1996; 48:1112-1115.
55. Frkanec R, Noethig-Laslo V, Mirosavljević K, Vraneš ić B, Tomašić J. A spin labeling study of immunomodulating peptidoglycan monomer and adamantyl-tripeptides entrapped into liposomes. Biochim Biophys Acta 2003; 1611:187-196.